What treatment can benefit women using hormone therapy who experience vaginal atrophy and frequent urinary tract infections?

Topical estrogen is an effective treatment option for women experiencing vaginal atrophy and frequent urinary tract infections, especially those who are already using systemic hormone therapy. Vaginal atrophy, which involves thinning, drying, and inflammation of the vaginal walls as a result of decreased estrogen levels, can lead to discomfort and a predisposition to infections.

Topical estrogen therapy specifically targets the vaginal tissues, delivering estrogen locally to alleviate symptoms, improve vaginal health, and restore the natural moisture and elasticity of the vaginal walls. This localized treatment can help minimize systemic side effects while effectively addressing vaginal dryness and associated infections, making it a suitable choice for women looking for relief.

In contrast, systemic hormone therapy can have broader effects on the entire body and may not be necessary if the primary issue is localized vaginal atrophy. Antibiotics could manage an existing urinary tract infection, but they do not address the underlying cause of recurrent infections related to vaginal atrophy. Vaginal lubricants can provide symptomatic relief during intercourse but do not resolve the atrophy or strengthen the vaginal epithelium. Therefore, topical estrogen is the most appropriate treatment option for the scenario presented.